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In patients with diabetes, atherosclerosis is the main reason for impaired life expectancy, and diabetic
nephropathy and retinopathy are the largest contributors to end-stage renal disease and blindness, respec-
tively. An improved therapeutic approach to combat diabetic vascular complications might include blocking
mechanisms of injury as well as promoting protective or regenerating factors, for example by enhancing the
action of insulin-regulated genes in endothelial cells, promoting gene programs leading to induction of
antioxidant or anti-inflammatory factors, or improving the sensitivity to vascular cell survival factors. Such
strategies could help prevent complications despite suboptimal metabolic control.Introduction
The vascular complications of diabetes are among the most
serious manifestations of the disease. Atherosclerosis is the
main reason for impaired life expectancy in patients with dia-
betes, whereas diabetic nephropathy and retinopathy are the
largest contributors to end-stage renal disease and blindness,
respectively. The most well-established clinical advances in pre-
venting vascular complications of diabetes include intensive
blood glucose lowering, which decreases the risk of nephropathy
and retinopathy; antihypertensive medicine, which decreases
the risk of cardiovascular disease, nephropathy, and retinopathy;
panretinal photocoagulation and agents targeting vascular
endothelial growth factor (VEGF), which slow the progression
of diabetic retinopathy; and statin therapy, which reduces the
risk of cardiovascular disease. Despite these advances, diabetes
complications remain an enormous problem. The public health
impact of diabetes will continue to grow due to the expected
increase in the prevalence of the disease.
Although lowering blood glucose delays the onset of
nephropathy and retinopathy, cardiovascular disease in dia-
betes shows less robust association with hyperglycemia and
less benefit from glucose-lowering therapy. Moreover, it is clear
that diabetes is associated with increased cardiovascular risk
beyond what is explained by dyslipidemia or hypertension,
both of which are more common in patients with diabetes.
Accordingly, insulin resistance and its biological effects in
various tissues may be more important factors than hyper-
glycemia in mediating atherothrombotic complications, particu-
larly in type 2 diabetes. Despite these insights, there are
few therapies targeting vascular abnormalities specific for
diabetes.
Advances in understanding the vascular pathology of diabetes
have made it clear that the pathogenesis of diabetic vascular
complications is determined by a balance between molecular
mechanisms of injury and endogenous protective factors
(Figure 1). Both aspects of disease mechanisms provide targets
for prevention even during suboptimal metabolic control. To
emphasize these concepts, the current review will juxtapose
some of the current knowledge about mechanisms of injury,
with selected literature describing protective factors.20 Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc.Pathogenesis of Vascular Complications
The complications of diabetes and the vascular components in
their pathogenesis are so intertwined that often one aspect is
not considered separately from the other. However, mecha-
nisms unrelated to vascular dysfunction are a part of the patho-
genesis of these complications, for example in renal tubules and
in retinal neurons. These mechanisms will not be considered
further here. Diabetic neuropathy, which traditionally is counted
among microvascular complications, is likely caused more by
abnormalities in neuronal cells than by microvascular dysfunc-
tion; molecular mechanisms of diabetic neuropathy have been
reviewed recently elsewhere (Vincent et al., 2011).
Atherosclerosis in Diabetes
The pathology of atherosclerotic lesions in patients with diabetes
is indistinguishable from lesions in patients in whom another
characteristic, like hypercholesterolemia or smoking, is the
major risk factor. Cholesterol, in particular LDL cholesterol, is
usually considered the major contributor to atherosclerosis
susceptibility. However, patients with type 2 diabetes typically
do not have elevated cholesterol in low-density lipoprotein
(LDL), but rather a characteristic dyslipidemia of high triglycer-
ides, low HDL, and small, dense LDL (Sniderman et al., 2001).
Apolipoprotein B-containing and modified LDL retained in the
arterial intima recruits monocyte-derived macrophages, which
take up lipoproteins and differentiate into foam cells (Figure 2).
Cytokines and chemokines released from macrophage foam
cells and other immune cells recruit additional immune cells.
Overproduction of reactive oxygen species (ROS) as a result of
altered glucose metabolism and formation of advanced
glycation endproducts (AGE) further amplifies this process by
activating nuclear factor kB (NFkB) and other proinflammatory
pathways. In combination with endothelial cell insulin resistance,
these changes cause endothelial dysfunction manifesting itself
by increased expression of adhesion molecules and other
changes. The resulting leukocyte recruitment, perhaps com-
pounded by proliferation of plaque macrophages, further
increases leukocyte numbers in the intima. Proliferating vascular
smooth muscle cells are a major source of extracellular matrix in
the atherosclerotic plaque and to the fibrous cap covering the
plaque. Apoptosis of macrophages contributes to formation of
Figure 1. Selected Mechanisms of Injury
and Protective Factors Determining
Development of Diabetic Vascular
Complications
This diagram illustrates that in the normal state,
factors with protective functions in the vasculature
can render blood vessels less susceptible to
vascular disease and can counteract mechanisms
which promote vascular injury. In diabetes,
however, glucose and lipid metabolites promote
mechanisms of injury and, at the same time, inhibit
factors with protective functions in the vascula-
ture. Abbreviations are as follows: AGE, advanced
glycation endproducts; APC, activated protein C;
FFA, free fatty acids; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; NF-kB, nuclear
factor kB; PDGF, platelet-derived growth factor;
PKC, protein kinase C; ROS, reactive oxygen
species; VEGF, vascular endothelial growth factor.
Artwork by Leah A. Klein.
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metalloproteases and other enzymes from macrophages and
other cells breaks down the fibrous cap and causes plaque
rupture. This event can cause thrombosis when exposing the
necrotic core and other extracellular components to circulating
blood, precipitating the major life-threatening events in athero-
sclerosis, including myocardial infarction and stroke.
Diabetic Nephropathy
Patients with diabetes have increased glomerular perfusion and
plasma filtration owing to decreased resistance in both the
afferent and efferent arteriole. The most important early clinical
risk factor for diabetic nephropathy is albuminuria, which is
caused by hemodynamic changes and by impairment of the
glomerular filtration barrier. Changes to this barrier include
thickening and changed composition of the glomerular base-
ment membrane and regression of the cytoplasmic exten-
sions, or foot processes, of podocytes (Dronavalli et al., 2008)
(Figure 2). Proinflammatory and profibrotic signals from glomer-
ular cells and infiltrating macrophages cause mesangial expan-
sion consisting of accumulating extracellular matrix. Apoptosis
of podocytes and glomerular endothelial cells can ensue, with
glomerulosclerosis as the most advanced pathological change.
Abnormal function of tubules and tubolointerstitial fibrosis
develops in parallel with glomerular damage, possibly in re-
sponse to albuminuria.
Diabetic Retinopathy
The first pathological changes in diabetic retinopathy are
decreased pericyte coverage of retinal capillaries and acellular
capillaries representing apoptosis of pericytes and endothelial
cells (Hammes et al., 2011) (Figure 2). Vascular cell apoptosis
is caused by abnormal glucosemetabolism, activation of protein
kinase C (PKC), formation of AGE, increased production of ROS,
release of proinflammatory cytokines from Mu¨eller cells, or
microglia in the retina or from leukocytes adhering to capillary
endothelium, loss of survival signaling stimulated by platelet-
derived growth factor (PDGF), and other factors, and upregula-
tion of angiostatic factors like Tie2 (Hammes et al., 2011).
Impaired perfusion and retinal ischemia then cause upregulation
of angiogenic molecules including VEGF, erythropoietin, and
other vascular growth factors (Antonetti et al., 2012). Thesefactors promote proliferative diabetic retinopathy and lead
to increased vascular leakage, with contributions from the
kallikrein-bradykinin signaling and other pathways (Antonetti
et al., 2012). Vision loss can be secondary to preretinal angiogen-
esis, which can cause bleeding into the vitreous or formation of
an epiretinal membrane. Another major cause of impaired vision
is macular edema.
Similarities and Differences in Vascular Cell Biology
in Diabetes
The alterations in cellular homeostasis and regulation of vascular
physiology which leads to vascular complications affect all major
functions of vascular cells (Figure 3). Increased vascular perme-
ability and apoptosis of specific vascular cells, including retinal
pericytes and glomerular podocytes, are prominent features of
diabetic nephropathy and retinopathy. Macrophage apoptosis
is important for plaque necrosis in atherosclerosis. Vascular
beds in most tissues are affected by increased leukocyte adhe-
sion, which may participate in the pathogenesis of all these
complications and is certainly pivotal for development of athero-
sclerosis. Proliferation of vascular smooth muscle cells deter-
mines remodeling of atherosclerotic plaques and formation of
fibrous caps, and proliferation of capillary endothelial cells drives
diabetic proliferative retinopathy. Alterations in hemostasis are
most significant during development of thrombi associated
with atherosclerotic plaques and in microscopic bleeding from
retinal vessels. Finally, blood flow is increased early in diabetic
nephropathy but decreased in the retina due to capillary occlu-
sion and in large arteries as a result of development of occlusive
plaques (Figure 3). These general changes reflect that similar
systemic factors such as hyperglycemia, insulin resistance,
and dyslipidemia are present in all vascular tissue. However,
they also highlight the importance of tissue-specific differences
in the response to common metabolic abnormalities.
Molecular Mechanisms of Injury
A host of abnormalities in cell signaling, gene expression, and
regulation of cell biology and physiology have been described
in diabetes, and it appears likely that many of these abnormali-
ties operate concurrently during development of diabetic
vascular complications. Some of these mechanisms may beCell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc. 21
Figure 2. Important Histopathological Changes during Development of Atherosclerosis, Nephropathy, and Retinopathy in Diabetes
This schematic illustration shows pathological changes in a coronary artery (left) and in glomerular and retinal capillaries (middle and right, respectively) in
diabetes. Some of the main features are accumulation of lipid-laden macrophages in the atherosclerotic plaque and subsequent macrophage apoptosis (left);
podocyte apoptosis, thickening of the glomerular basement membrane, and breakdown of the filtration barrier in the renal glomeruli (middle); and pericyte and
endothelial cell apoptosis, vascular leakage, and hemorrhage in the retina (right). Proportions, in particular size of the artery relative to the capillaries, are not to
scale. Artwork by Leah A. Klein.
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generally they are relevant for development of complications in
several organs. Therefore, they are described here without
a strict association with a specific pathology.
PKC
PKC is a ubiquitously expressed enzyme which participates in
a wide range of intracellular signaling. Its activity is upregulated
in vascular tissue in diabetes, including in large arteries, the renal
glomeruli, and the retina. Among the ten mammalian isoforms of
PKC, the a, b, and d isoforms have been most consistently impli-22 Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc.cated in diabetic vascular complications. Gene knockout of
PKCb in a mouse model of retinal ischemia reduces proliferative
retinopathy (Suzuma et al., 2002), and knockout of PKCd in mice
with streptozotocin-induced diabetes prevents retinal pericyte
apoptosis (Geraldes et al., 2009). Mesangial expansion and
albuminuria in mice with streptozotocin-induced diabetes are
improved in both PKCb (Ohshiro et al., 2006) and PKCd (Mima
et al., 2012) knockout mice, and deletion of PKCb in apoE null
mice results in a large reduction of atherosclerosis (Harja et al.,
2009).
Figure 3. General Abnormalities of Vascular Function in Diabetes
Diagram showing changes in some of the main functions of blood vessels. The
diagram should be read like a table, with the affected vessel in each of three
columns and functions row by row. In arteries, blood flow may be reduced
because of atherosclerosi. Glomerular perfusion is increased in early diabetes
and the retina becomes ischemic because of insufficient blood flow. Leuko-
cyte adhesion is present in all three vascular beds but has a particularly
important role in atherogenesis. Increased vascular permeability has a prom-
inent role in the glomerular and retinal capillary. Cellular proliferation occurs for
vascular smoothmuscle cells in the atherosclerotic plaques and for endothelial
cells in proliferative diabetic retinopathy. Apoptosis has important implications
when it occurs in macrophages in atherosclerosis and is a major characteristic
of the histopathology in diabetic nephropathy and retinopathy. Vessels in gray
represent a less prominent abnormality for the vessel in question. Artwork by
Leah A. Klein.
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bisindolylmaleimide compound ruboxistaurin, and oral treat-
ment with this drug ameliorates vascular complications in animal
models of diabetes. For example, ruboxistaurin improves
glomerular and retinal hemodynamics in experimental diabetes(Ishii et al., 1996), prevents albuminuria and mesangial expan-
sion (Koya et al., 2000), blocks retinal vascular permeability
(Aiello et al., 1997), and reduces atherosclerosis (Harja et al.,
2009). Effects of PKCb inhibition were established in preclinical
models of early-stage complications, but so far this treatment
has only been tested in patients with late-stage complications.
Ruboxistaurin was shown to be effective in the treatment of
patients with advanced nephropathy (Tuttle et al., 2005) and
late-stage retinopathy (Aiello et al., 2011). These trials showed
that the PKCb inhibitor reduced albuminuria, prevented a decline
in glomerular filtration rate (Tuttle et al., 2005), and improved the
incidence of vision loss (Aiello et al., 2011). However, further
phase III clinical trials of ruboxistaurin or other PKCb inhibitors
are needed, and inhibitors of PKCd for clinical use are warranted.
PKC isoforms are grouped as classic, novel, and atypical
based on structure and modes of activation. PKCb and PKCd
belong to the classic and novel groups, respectively, which
can both be activated by the lipid diacylglycerol (DAG). In dia-
betes, intracellular DAG abundance is increased in vascular
tissue through de novo synthesis via glyceraldehyde 3-phos-
phate and phosphatidic acid or from nonesterified fatty acids.
Alternatively, increased DAG synthesis can occur from the
glycolytic intermediate dihydroxyacetone phosphate which
accumulates when the glycolytic enzyme glyceraldehyde
3-phosphate dehydrogenase (GAPDH) is inhibited by poly(ADP-
ribosyl)ation during high glucose concentrations (Du et al.,
2003). Increased DAG mass causes a relatively low, but sus-
tained, level of PKC activation, quite different from the transient
activation of PKC seen after activation of G protein-coupled
receptors. High glucose concentrations can also increase PKC
activity through increases in transcriptional upregulation, as
seen in the case of increased expression of PKCd in retinal
vascular cells (Geraldes et al., 2009) and renal glomeruli (Mima
et al., 2012) (Figure 4).
Once activated by hyperglycemia or free fatty acids, PKC
promotes retinopathy through several different downstream
signaling pathways. For example, the mechanism for reduced
retinal blood flow mediated by PKCb involves endothelin-1
(ET-1), which is upregulated in the retina of diabetic rats (Yokota
et al., 2003). This induction of retinal ET-1 can be blocked by
treating the animals with ruboxistaurin (Yokota et al., 2003).
Diabetic macular edema is mediated in part by VEGF through
signaling involving PKCb (Aiello et al., 1997), in part by increasing
phosphorylation of occludin, a component of tight junctions,
leading to increased vascular permeability (Murakami et al.,
2012). High glucose concentrations may also increase endothe-
lial cell permeability through PKCa (Hempel et al., 1997). In addi-
tion, activation of PKCd can enhance the apoptosis of retinal
pericytes via multiple mechanisms including activation of p38
MAPK, NADPH oxidase, and NF-kB.
Several isoforms of PKC are involved in the development of
diabetic kidney disease. PKCa and PKCb1 are activated in renal
glomeruli in mice with streptozotocin-induced diabetes, and
50% of the increase in PKC activity in renal glomeruli is pre-
vented in mice with knockout of PKCb (Ohshiro et al., 2006). In
wild-type mice, diabetes increases activity of NADPH oxidase
and induces expression of ET-1, VEGF, transforming growth
factor b (TGF-b), connective tissue growth factor (CTGF), and
collagen IV and VI. These changes are partly prevented inCell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc. 23
Figure 4. Activation of SHP-1 and Inhibition of Survival Pathways in
Diabetes
Schematic illustration of mechanisms promoting apoptosis in retinal pericytes
and glomerular podocytes. PDGF and VEGF receptor signaling promotes cell
survival. In diabetes, activation of SHP-1 can dephosphorylate these receptors
and contribute to apoptosis. Abbreviations are as follows: MAPK, mitogen-
activated protein kinase; NF-kB, nuclear factor kB; PDGF, platelet-derived
growth factor; PDGFR, PDGF receptor; PI3K, phosphatidylinositol 3-kinase;
PKC, protein kinase C; ROS, reactive oxygen species; SHP-1, Src homology-2
domain-containing phosphatase-1; VEGF, vascular endothelial growth factor;
VEGFR2, VEGF receptor-2. Artwork by Leah A. Klein.
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vance of these findings for human disease, polymorphisms in the
PKCb1 gene have been associated with end-stage renal disease
in Chinese patients with type 2 diabetes (Ma et al., 2010). Activa-
tion of PKCa causes upregulation of VEGF through activation of
NADPH (Thallas-Bonke et al., 2008), and PKCa knockout mice
are protected against loss of basement membrane proteogly-
cans and induction of VEGF (Menne et al., 2004). Surprisingly,
PKCε may have effects on diabetic nephropathy opposite of
PKCa, PKCb, and PKCd. One study showed that knockout of
PKCε upregulates renal TGFb1 and its downstream signaling
and increases expression of fibronectin and collagen IV, causing
glomerular and tuboloinsterstitial fibrosis and development of
albuminuria (Meier et al., 2007). These changes are further
aggravated by diabetes (Meier et al., 2007). Therefore, PKCε
may act as a protective factor by reducing kidney damage.
Further studies are necessary to understand the role of PKCε
in complications of diabetes.
As shown by these and other studies, the evidence for activa-
tion of PKC in the diabetic retina and kidney and the causal rela-24 Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc.tionship between PKC activation and vascular complications is
very strong. The interest in developing new PKC inhibitors is
growing because of recent studies showing roles for PKCd and
PKCε in liver insulin resistance in obesity. However, to achieve
clinically significant effects in the prevention or treatment of
diabetic retinopathy and nephropathy, inhibition of multiple
PKC isoforms, including a, b, and d, may be needed.
Hyperactive Metabolic Pathways
Increased cellular glucose uptake increases the flux of glucose
through the polyol pathway (also known as the sorbitol pathway).
This pathway consumes NADPH in the aldose reductase reac-
tion and reduces NAD+ in the sorbitol reductase reaction (Brown-
lee, 2001). Activation of the polyol pathway may result not only
from increased availability of glucose, the upstream substrate
for the pathway, but also from inactivation of GAPDH. This can
occur through addition of ADP-ribose moieties to GAPDH by
the enzyme poly(ADP-ribose) polymerase (PARP) after its activa-
tion by reactive oxygen (Du et al., 2003). GAPDH is necessary for
the glycolytic conversion of glyceraldehyde 3-phosphate. There-
fore, GAPDH inactivation leads to increased levels of glyceralde-
hyde 3-phosphate, which in turn causes increased production of
methylglyoxal, an AGE precursor, or de novo synthesis of DAG,
a PKC activator (Brownlee, 2001).
A hyperactive polyol pathway can also adversely affect cellular
homeostasis by depleting cytosolic NADPH, which is necessary
to maintain the primary intracellular antioxidant, glutathione, in
its reduced state. In addition, pools of intracellular NADPH can
be diminished by a different mechanism whereby increased
glucose concentrations inhibit glucose 6-phosphate dehydroge-
nase. This enzyme catalyzes the first intermediary reaction in the
pentose phosphate pathway, the primary source of NADPH (Xu
et al., 2010).
Early animal studies of aldose reductase inhibition showed
promise with regard to an effect on diabetic retinopathy or
nephropathy, but clinical trials failed to confirm such effects in
patients with diabetes. A renewed interest in aldose reductase
has emerged from studies of atherosclerosis in diabetesmodels.
Ubiquitous overexpression of aldose reductase in mice
increased atherosclerosis (Vikramadithyan et al., 2005). Para-
doxically, increased atherosclerosis was also described in
mice with knockout of the aldose reductase gene or treatment
with an aldose reductase inhibitor (Srivastava et al., 2009).
Therefore, further study is necessary to determine the contribu-
tion of aldose reductase pathway to atherosclerosis develop-
ment in diabetes.
Oxidative Stress
Production of superoxide and other ROS in the vascular wall
plays a prominent role in the pathogenesis of vascular disease
in general and has characteristic features in diabetes. A major
source of superoxide in vascular cells is thought to be an oxidase
which resembles the phagocytic NADPH oxidase but favors
NADH as a substrate (Lasse`gue et al., 2012). It is expressed in
endothelial cells and vascular smooth muscle cells (Lasse`gue
et al., 2012). Expression and activity of vascular NADH oxidase
are increased in rat models of type 1 (Hink et al., 2001) and
type 2 (Kim et al., 2002) diabetes. This enzyme may be activated
by an increase in the NADH/NAD+ ratio, which in diabetes may
be caused by an increased flux through the polyol pathway
(see above) or activation of PARP (Garcia Soriano et al., 2001).
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glucose and free fatty acid concentrations through PKC activa-
tion (Inoguchi et al., 2000). Clinical trials have been initiated to
test the value of isoform-specific inhibitors of NADPH oxidases
in prevention of diabetic complications (Lasse`gue et al., 2012).
Mitochondria are another important source of ROS. In mito-
chondria, the citric acid cycle provides NADH and FADH2 that
can act as electron donors for the electron transport chain,
creating a proton gradient over the inner mitochondrial mem-
brane (Brownlee, 2001). When intracellular glucose concentra-
tion increases in diabetes and thereby yields excessive reducing
equivalents for this process, the proton gradient increases and
inhibits the transfer of electrons from reduced coenzyme Q
(ubiquinone) to complex III of the electron transport chain
(Brownlee, 2001). Instead, electrons are transferred to molecular
oxygen, causing production of superoxide.
Nitric oxide (NO) can neutralize ROS, but paradoxically, endo-
thelial NO synthase (eNOS) can become a source of ROS if an
already pro-oxidant redox state favors oxidation of the eNOS
cofactor tetrahydrobiopterin (BH4). This leads to uncoupling of
electron transport in eNOS and release of superoxide (Laursen
et al., 2001). By promoting DNA strand breaks, oxidative stress
can activate PARP, which in turn can activate NFkB and cause
endothelial dysfunction (Garcia Soriano et al., 2001). Oxidative
stress can also inhibit the proteasomal degradation of homeodo-
main-interacting protein kinase 2 (HIPK2), which promotes
kidney fibrosis through activation of p53, TGF-b, and Wnt (Jin
et al., 2012).
Glycemic Modification of Proteins
Modification of extracellular and intracellular proteins by sugars
can result in the formation of AGE which can alter protein struc-
ture or function and activate proinflammatory and other signaling
through cell-surface receptors (Yan et al., 2010). It is thought that
increased concentrations of AGE in diabetes are directly corre-
lated with the level of hyperglycemia, although it has been
proposed that the rate of AGE formation could also be deter-
mined by changes in themetabolism of glucose-derived reactive
intermediates, irrespective of glucose concentrations (Fleming
et al., 2012). AGE formation can occur via a nonenzymatic reac-
tion between glucose and protein through the Amadori product
(1-amino-1-deoxyfructose adducts to lysine). However, much
faster reactions take place between proteins and intracellularly
formed dicarbonyls including 3-deoxyglucosone, glyoxal, and
methylglyoxal. These processes are accelerated by ROS.
The most prevalent AGE is carboxymethyllysine. Additional
nonenzymatic modification results in crosslinking of proteins.
Due to their long turnover rate, structural extracellular proteins
such as collagen are particularly susceptible to AGE modifica-
tion. AGE has been demonstrated in numerous tissues in both
types of diabetes, such as the retina, the glomeruli, and the
aorta.
AGEmodification of extracellular matrix proteins and signaling
molecules may alter their function. In addition, AGE-modified
extracellular proteins may act by binding to receptors, the
most well-characterized being receptor for AGE (RAGE) (Yan
et al., 2010). The ability of RAGE signaling to cause diabetic
complications has been directly demonstrated in a study in
which transgenic mice overexpressing iNOS targeted to b cells,
providing a model for type 1 diabetes, were crossbred withtransgenic mice overexpressing RAGE. These double transgenic
mice developed accelerated glomerular lesions (Yamamoto
et al., 2001), which could be prevented by an AGE inhibitor
(Yamamoto et al., 2001). A soluble receptor for RAGE prevents
development of increased vascular permeability and atheroscle-
rosis (Park et al., 1998) in experimental diabetes. Clinical trials
are ongoing for small molecule antagonists of RAGE (Yan
et al., 2010).
The Renin-Angiotensin System
A large number of clinical trials have unequivocally shown that
treatment with angiotensin-converting enzyme (ACE) inhibitors,
angiotensin type 1 (AT1) receptor blockers, or their combination
can prevent the incidence of renal disease or delay the progres-
sion to renal failure (Burnier and Zanchi, 2006). However,
analysis of renal biopsies from type 1 diabetic patients treated
with these drugs showed no improvement in glomerular
pathology, indicating that inhibition of the renin-angiotensin
systemmay slow down only the progression of functional impair-
ment in diabetic nephropathy (Mauer et al., 2009). Many studies
also have demonstrated that treatment with ACE inhibitors can
prevent diabetic retinopathy.
Angiotensin I and II are produced locally in the kidney, and part
of the renoprotective effect of ACE inhibition is a decrease of
glomerular capillary pressure rather than a lowering of systemic
blood pressure. It has been shown that angiotensin II actions
may lead to kidney damage through induction of local factors,
including extracellular matrix protein synthesis via TGF-b
(Kagami et al., 1994). A similar mechanism may contribute to
cardiac fibrosis (Kawano et al., 2000). Apart from promoting
extracellular matrix protein synthesis in cardiac fibroblasts,
angiotensin II can induce myocardial PAI-1 expression, which
in turn can inhibit extracellular matrix breakdown through inhibi-
tion of metalloproteinases (Kawano et al., 2000).
Plasma Kallikrein and Bradykinin
Retinal vascular permeability is regulated by activation of
bradykinin B1 and B2 receptors, and B1 receptor num-
bers are increased in diabetes. The proteolytic cleavage of
high-molecular-weight kininogen mediated by plasma kallikrein
(PK) results in the increased extracellular expression in the retina
of several isoforms of bradykinin. One mechanism by which this
kallikrein-kinin system is activated in diabetes is in response to
the release of carbonic anhydrase I (CA-I) by red blood cells after
microscopic hemorrhage in the retina and into the vitreous (Gao
et al., 2007). In a proteomic analysis, CA-I was found to be
increased in vitreous samples from patients with proliferative
diabetic retinopathy compared to samples from patients without
diabetes or diabetic patients without retinopathy (Gao et al.,
2007). Injection of CA-I into the vitreous in rats increased intraoc-
ular pH, which in turn activated PK and increased retinal vascular
permeability. These effects could be blocked by inhibitors of PK
or bradykinin receptors (Gao et al., 2007). Intravitreal injection of
PK increased retinal vascular permeability acutely in diabetic
rats by a greater extent than did nondiabetic controls and
caused retinal thickening (Clermont et al., 2011). PK inhibitors
(Clermont et al., 2011) or bradykinin receptor blockers (Abdouh
et al., 2008) reduce retinal vascular permeability in rats with
streptozotocin-induced diabetes. Inhibitors of PK are currently
being developed as a possible treatment of diabetic macular
edema.Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc. 25
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High-glucose concentrations and diabetes can activate Src
homology-2 domain-containing phosphatase-1 (SHP-1), a tyro-
sine phosphatase, in several tissues, including the retina and
renal glomeruli. This leads to the dephosphorylation and deacti-
vation of specific growth factor receptors critical for survival of
pericytes in the retina and podocytes in the kidney (Geraldes
et al., 2009). In the diabetic retina, SHP-1 activation can desen-
sitize pericytes to PDGF and cause pericyte apoptosis, an initi-
ating step in the development of diabetic retinopathy (Geraldes
et al., 2009). In the renal glomeruli, impairment of VEGF survival
signaling by upregulation of SHP-1 expression can lead to
increased podocyte apoptosis and endothelial dysfunction
(Mima et al., 2012).
Upregulation of SHP-1 in diabetes is dependent upon activa-
tion of PKCd and p38 MAPK (Geraldes et al., 2009; Mima et al.,
2012) (Figure 4). The diabetes-induced upregulation of p38
MAPK and SHP-1 is prevented in PKCd knockout mice, and
these animals are protected from apoptosis of retinal pericytes
and from mesangial expansion and albuminuria (Geraldes
et al., 2009; Mima et al., 2012). Retinal pericyte apoptosis has
been shown to involve activation of NFkB. However, upregula-
tion of SHP-1 in the diabetic retina and glomerulus is indepen-
dent of NFkB activation (Geraldes et al., 2009; Mima et al.,
2012) (Figure 4). Therefore, inhibition of SHP-1 is a potential
novel approach to preserve survival signaling in vascular cells.
ER Stress
The endoplasmatic reticulum (ER) plays important roles in Ca2+
and redox homeostasis, lipid biosynthesis, and protein folding.
Increases in protein synthesis, protein misfolding, or perturba-
tions in Ca2+ and redox balance can disturb ER function, leading
to the development of ER stress. In response, a coordinated
program referred to as the unfolded protein response (UPR) is
initiated to reduce translation and increase protein folding
capacity in an attempt to restore ER homeostasis. Under condi-
tions of chronic, unresolved ER stress, the UPR can also initiate
signaling events that promote apoptosis.
ER stress has emerged as an important mechanism linking
obesity and the development of insulin resistance. It is also
involved in pancreatic b cell failure due to chronic activation of
this pathway in the hyperinsulinemic state associated with
obesity and insulin resistance. Although the underlying mecha-
nisms that cause ER stress in the context of obesity have only
begun to be elucidated, likely causes include increases in protein
synthesis in response to nutrient excess, elevated levels of lipids,
and changes in ER calcium homeostasis due to alterations in
sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA) function
(Park et al., 2010b).
Recently, a central role has been described for PI3K regulatory
subunits as modulators of the UPR by virtue of their ability to
regulate the nuclear translocation of X box binding protein 1
(XBP-1). The regulatory p85 subunit of PI3K promotes nuclear
translocation of XBP-1 by binding to this transcription factor as
a p85a or p85b monomer (Park et al., 2010a; Winnay et al.,
2010). However, this interaction competes with formation of
p85a/p85b heterodimers (Park et al., 2010a). Insulin stimulation
leads to a disruption of p85a/b heterodimers (Park et al.,
2010a), thereby allowing monomeric p85 to promote XBP-1
nuclear translocation and subsequent upregulation of UPR26 Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc.target genes (Park et al., 2010a; Winnay et al., 2010). In the ob/
ob mouse model of obesity, this effect of insulin is lost and
nuclear translocation of XBP-1 is profoundly impaired, thereby
preventing activation of the UPR and resolution of ER stress.
Collectively, these data suggest that insulin resistance may
fundamentally alter the cellular response to ER stress.
A variety of studies have also implicated ER dysfunction in the
pathogenesis of atherosclerosis. For example, UPR target genes
are upregulated in areas of the aorta susceptible to atheroscle-
rosis (Civelek et al., 2009). Moreover, it has been demonstrated
that ER stress is induced in endothelial cells by proatheroscler-
otic factors including oxidized LDL or increased intracellular
concentrations of glutamine. In addition, macrophage ER stress
promotes apoptosis of atherosclerotic plaque macrophages,
which can lead to necrotic core formation and thrombosis.
Accordingly, knockout of the UPR target gene C/EBPa-homolo-
gous protein (CHOP) in macrophages prevents macrophage
apoptosis (Thorp et al., 2009). Macrophage apoptosis and
plaque rupture can be partly prevented by a pharmacological
chaperone, implicating ER stress as a major mechanism regu-
lating these processes (Erbay et al., 2009).
UPR genes are upregulated in kidney tissue from patients with
diabetes, and ER stress may be a mediator of diabetic nephrop-
athy. Mice with streptozotocin-induced diabetes and knockout
of CHOP are protected from diabetic nephropathy (Wu et al.,
2010). In the retina of rats with streptozotocin-induced diabetes,
ER stress is also involved in upregulation of inflammatory genes
and VEGF and in mediating increased vascular permeability
(Zhong et al., 2012). These and other findings have prompted
development of drugs which can ameliorate ER stress in
patients, including synthetic chaperones to promote protein
folding and inhibitors of CHOP and other molecules enabling
the UPR.
Protective Factors
As knowledge about homeostasis of vascular cells has accumu-
lated, it has become clear that some factors play a protective role
for the function and survival of cells involved in the vascular
complications of diabetes (Figure 1). In the Medalist Study
from the Joslin Diabetes Center, more than 40% of a large group
of insulin-requiring diabetic patients with disease duration of 50
years or longer were free from significant retinal and renal
dysfunction (Keenan et al., 2007; Sun et al., 2011). The presence
of microvascular complications did not correlate with glycemic
control, suggesting the presence of endogenous protective
factors in this unusual group of patients with diabetes of extreme
duration. The possibility that endogenous protective factors are
common in the general population of patients with diabetes is
supported by the finding that over half of diabetic patients with
microalbuminuria have regression of this marker over 6 years
of followup (Perkins et al., 2003). Some factors with well-estab-
lished function have only recently been perceived as protective.
For example, the focus on insulin action has traditionally been its
metabolic actions, but studies now show that this hormone
counteracts excessive leukocyte-endothelial cell adhesion and
atherosclerosis development (Rask-Madsen et al., 2010) and is
an important survival factor for glomerular podocytes (Welsh
et al., 2010). As another example, activated protein C (APC)
has been known for roles in hemostasis but has recently been
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(Isermann et al., 2007).
Insulin
Insulin receptors are present on vascular cells and cells recruited
to the vascular wall, among them endothelial cells, vascular
smooth muscle cells, pericytes, and macrophages. Insulin stim-
ulates signal transduction in these cells but does not regulate cell
metabolism in the same manner as classic insulin-sensitive cell
types. For example, endothelial cells express the insulin-
unresponsive glucose transporter GLUT1, but not GLUT4, which
increases cellular glucose uptake in response to insulin.
However, insulin has important effects on endothelial cell
homeostasis. Insulin can activate and upregulate gene expres-
sion of eNOS (Kuboki et al., 2000), which is considered to have
an antiatherosclerotic effect. Conversely, insulin can induce
expression of ET-1 (Oliver et al., 1991), which can promote
atherosclerosis. The overall effect, however, of endothelial cell
insulin resistance is acceleration of atherosclerosis, as demon-
strated in apoE null mice with knockout of the insulin receptor
(Insr) gene targeted to vascular endothelium (EIRAKO mice)
(Rask-Madsen et al., 2010). In these mice, atherosclerosis
increased by up to 2.9-fold compared to apoE null controls
with intact insulin receptors. Accelerated atherosclerosis in
EIRAKO mice occurred without changes in insulin levels, lipid
metabolism, insulin sensitivity, glucose tolerance, or blood pres-
sure. They had, however, increased leukocyte-endothelial cell
adhesion to endothelial cells, with up to a 4-fold increase in
leukocyte adhesion as measured during in vivo microscopy
(Rask-Madsen et al., 2010). Compared to their controls, there
was no difference in atherosclerosis development in apoE null
mice after replacing their bone marrow with grafts from EIRAKO
mice. Furthermore, increased leukocyte adhesion could be reca-
pitulated by injecting labeled monocytes from EIRAKO donors
into wild-type recipients, but not by injecting monocytes from
wild-type donors into EIRAKO recipients. These results indicated
that hematopoietic cells did not contribute significantly to the
increased leukocyte adhesion and atherosclerosis development
in EIRAKO mice. Additional experiments showed that insulin
downregulates VCAM1, an adhesion molecule critical for firm
leukocyte adhesion, and that VCAM1was upregulated in primary
endothelial cells from EIRAKO mice (Rask-Madsen et al., 2010).
FoxO nuclear factors mediate many actions of insulin which
require changes in gene transcription. Insulin inhibits FoxO
activity by activating Akt, which directly phosphorylates FoxO,
causing it to be excluded from the nucleus. Knockout of three
major FoxO isoforms in endothelial cells had a dramatic effect
on atherosclerosis in LDLR knockout mice while reducing
oxidative stress, increasing NO production, and decreasing
endothelial cells apoptosis (Tsuchiya et al., 2012). Therefore,
FoxO-regulated genes in endothelial cells are likely responsible
for the increased susceptibility to atherosclerosis caused by
endothelial cell insulin resistance and may prove to be useful
targets for prevention of cardiovascular disease.
Hypercholesterolemic mice with conditional knockout of the
Insr gene in myeloid cells (primarily monocytes and granulo-
cytes) (Baumgartl et al., 2006) or with bone marrow replaced
with hematopoietic cells from Insr null mice (Han et al., 2006)
had a modest decrease or increase in atherosclerosis, respec-
tively. Mice with bone marrow replaced with grafts from micewith heterozygous knockout of Insr and the gene encoding
IRS-1 showed no change in atherosclerosis development (Gal-
kina et al., 2012). Therefore, macrophage insulin signaling
appears to have little effect on atherosclerosis development.
However, impairment of insulin signaling in macrophages
causes increased rates of macrophage apoptosis, at least in
part by enhancing ER stress. Insulin can inhibit apoptosis by
downregulating macrophage scavenger receptors (Liang et al.,
2004), by activating Akt (Han et al., 2006), by inhibiting FoxO1
(Senokuchi et al., 2008), or by inhibiting XBP-1 (Park et al.,
2010a; Winnay et al., 2010).
Insulin receptor signaling also has a surprisingly profound
effect on podocyte survival. A study examined mice with gene
knockout of the insulin receptor targeted to podocytes (Welsh
et al., 2010) using promoter activity of either podocin or nephrin,
genes not expressed by other kidney cells. From 5weeks of age,
these mice developed albuminuria, effacement of podocyte foot
processes, and increased apoptosis together with more deposi-
tion of basal membrane components compared to control
animals. This pathology was quite similar to that seen in diabetic
nephropathy. Some animals also developed shrunken kidneys
with prevalent scar tissue, similar to the macroscopic appear-
ance of kidneys in late-stage diabetic nephropathy. These
changes were accompanied by mild worsening of kidney
function. This is notable because kidney function is not affected
by streptozotocin-induced diabetes, the most commonly
studied rodentmodel of diabetes, despite albuminuria and histo-
pathological changes.
Insulin increases expression of VEGF in several cell types, and
VEGF expression is decreased in the heart muscle of animals
with diabetes (Chou et al., 2002). Therefore, insulin could upre-
gulate VEGF, which in turn could act as a survival factor by auto-
crine or paracrine signaling to podocytes, endothelial cells, and
mesangial cells. Insulin could also prevent apoptosis by other
mechanisms, including inhibition of the proapoptotic molecule
caspase-9 (Hermann et al., 2000), by inhibition of the transcrip-
tion factor FoxO (Tsuchiya et al., 2012), or by upregulation of
antioxidant activity of heme oxygenase-1 (HO-1) (Geraldes and
King, 2010) (Figure 5).
Impairment of insulin action on arteries and glomeruli as
described abovemay contribute to formation and destabilization
of atherosclerotic plaques and to diabetic nephropathy in
patients with type 2 diabetes. Many of insulin’s protective effects
are mediated via the IRS/PI3K/Akt pathway, including upregula-
tion of eNOS (Naruse et al., 2006) and HO-1 (Geraldes and King,
2010). In contrast, some mechanisms of injury stimulated by
insulin are mediated by the Ras/MAPK pathway, such as induc-
tion of ET-1 (Oliver et al., 1991).
In diabetes or other conditions of insulin resistance, elevated
concentrations of glucose and free fatty acids can activate
PKC, causing selective inhibition of insulin signaling through
the PI3K pathway (Naruse et al., 2006) (Figure 5). Certain serine
residues on IRS-2 and on the p85 regulatory subunit of PI3K
have recently been identified as substrates for PKC, and phos-
phorylation of these sites inhibits insulin-stimulated PI3K
signaling (Maeno et al., 2012). Despite these changes, insulin
signaling through the Ras/MAPK pathway is preserved or
increased in insulin resistance (Jiang et al., 1999). This state of
selective insulin resistance has been demonstrated in animalCell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc. 27
Figure 5. Selective Insulin Resistance in Vascular Cells in Type 2
Diabetes
Schematic illustration of mechanisms causing impaired insulin signaling in
vascular endothelial and smooth muscle cells. ET-1, angiotensin II, and other
factors can be increased by the metabolic milieu and activate PKC. Activated
PKC, in turn, can phosphorylate IRS proteins, the p85 subunit of PI3K, and
other signaling molecules. In this state, insulin-stimulated activation of the
PI3K signaling is inhibited, while signaling through the MAPK pathway is
preserved or enhanced. Selective insulin resistance in vascular cells causes
impaired vasodilation and angiogenesis, reduced antioxidant effects, and
increased leukocyte adhesion. Abbreviations (see also Figure 3) are as follows:
eNOS, endothelial nitric oxide synthase; ET-1, endothelin-1; FFA, free fatty
acids; HO-1, heme oxygenase-1; INSR, insulin receptor; IRS, insulin receptor
substrate; TNF-a, tumor necrosis factor a; VCAM-1, vascular cell adhesion
molecule 1. Artwork by Leah A. Klein.
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(Gogg et al., 2009). Hyperinsulinemia in type 2 diabetes could
conceivably promote vascular disease through induction of
ET-1 or other factors induced by MAPK signaling. However,
a mouse model of hyperinsulinemia with preserved vascular
tissue insulin signaling did not show increased atherosclerosis
(Rask-Madsen et al., 2012), suggesting that the vascular wall
may be less affected by hyperinsulinemia than by vascular cell
insulin resistance. Future studies will be needed to determine
whether enhancement of signaling through the PI3K pathway
can ameliorate endothelial dysfunction and atherosclerosis28 Cell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc.development in type 2 diabetes and other insulin-resistant
states.
Antioxidant Enzymes
Despite overwhelming preclinical evidence showing that oxida-
tive stress is involved in vascular complications, an amount of
resignation has dominated clinical translation of this knowledge
because most large trials of antioxidants have failed to show
significant advantages. Researchers with an unperturbed opti-
mism about the importance of oxidative stress mechanisms
argued that antioxidant activity needed to be induced among
endogenous systems, not by exogenously provided com-
pounds like antioxidant vitamins, because they would be
depleted or not reach intracellular locations (Wassmann et al.,
2004). This point of view has been supported by results from
clinical trials of bardoxolone methyl (BARD) (Pergola et al.,
2011). A main mechanism of action for this drug is to activate
nuclear factor (erythroid-derived 2)-like 2 (Nrf2). This nuclear
factor upregulates a gene program of molecules with antioxi-
dant activity called phase 2 genes, including HO-1 and enzymes
in the glutathione biosynthesis pathway. Nrf2 translocation to
the nucleus is inhibited by kelch-like ECH-associated protein
1 (Keap1), a repressor which binds Nrf2 in the cytoplasm and
promotes Nrf2 proteasomal degradation. BARD interacts with
cysteine residues on Keap1, making it unable to repress Nrf2,
which then activates transcription of phase 2 genes.
Results from a trial of BARD in patients with advanced chronic
kidney disease showed an improvement in GFR up to 1 year after
start of treatment (Pergola et al., 2011). This is a remarkable
result, and a trial is ongoing to evaluate the efficacy of BARD
on progression to end-stage renal disease. An increase in the
rate of albuminuria during BARD treatment and the loss of
most of the effect on GFR 4 weeks after withdrawal of BARD
was observed, so additional studies are needed to understand
kidney function during BARD treatment, in particular how renal
hemodynamics are affected.
PDGF
PDGF expressed by retinal endothelial cells plays a role both in
vascular cell survival and proliferative retinopathy (Lei et al.,
2010). During sprouting angiogenesis, PDGF is produced by
endothelial tip cells and acts through PDGF receptor-b ex-
pressed by pericytes. This signal recruits pericytes to developing
blood vessels. Pericytes, in turn, can support endothelial cell
survival as well as suppress endothelial cell proliferation. This
is demonstrated by findings in PDGF knockout mouse embryos
which show pericyte loss and endothelial cell proliferation
(Lindahl et al., 1997). Mice with heterozygous deletion of the
PDGF gene have increased frequency of acellular capillaries, in
particular after induction of diabetes, but also an increased
tendency for retinal neovascularization during ischemic retinop-
athy (Hammes et al., 2002). PDGF necessary for supporting
pericytes is likely released from endothelial cells because dele-
tion of the PDGF gene targeted to endothelium shows similar
pathology as whole-body deletion. Consistent with this, deletion
of PDGF-B in neurons, another source of PDGF-B, does not alter
pericyte coverage in the brain. As described above, we have re-
ported that hyperglycemia can inhibit survival effects of PDGF by
upregulation of SHP-1, which causes dephosphorylation of the
PDGF receptor in pericytes and possibly also in podocytes (Ger-
aldes et al., 2009).
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Expression of TGF-b is increased in blood vessels in many
vascular beds in diabetes and has been viewed as a causative
factor for development of fibrosis in the kidney, myocardium,
and other tissues. Among many preclinical studies, one showed
that in db/dbmice, treatment with a neutralizing antibody toward
TGF-b prevents glomerulosclerosis and impairment of creatinine
clearance in diabetic animals (Ziyadeh et al., 2000). However,
a profibrotic effect can be beneficial in the context of certain
vascular complications, as in atherosclerotic plaques where
thinning of the fibrous plaque is a central event in precipitation
of thrombosis. In addition, TGF-b has an anti-inflammatory effect
onmacrophages and is a negative regulator of T cells and B cells
and, therefore, may have protective actions due to an anti-
inflammatory effect.
Consistent with such beneficial roles of TGF-b, intraperitoneal
injection of recombinant soluble TGF-b receptor II in apoE null
mice increased inflammatory cells in the aorta and decreased
collagen content (Lutgens et al., 2002). Similar results were ob-
tained in a separate study by treatment of apoE null mice with
antibodies toward either of three different TGF-b isoforms.
Conversely, an inducible TGF-b1 transgene expressed in cardi-
omyocytes of apoE null mice, through elevations in plasma
concentrations of TGF-b1, decreased signs of inflammation in
the aorta and increased aortic collagen deposition (Frutkin
et al., 2009). These diverse roles of TGF-b are a challenge for
using it as a drug target. Development of targeted nanoparticles
or other means of tissue-specific drug delivery may allow inhibi-
tion of TGF-b signaling in the kidney and augmentation of TGF-b
signaling in arteries affected by atherosclerosis.
VEGF
Neutralization of VEGF is already in off-label use for treatment of
proliferative diabetic retinopathy and macular edema and has
been suggested as a therapy for diabetic nephropathy (Chen
and Ziyadeh, 2008). However, the increased levels of VEGF in
both tissues are likely an appropriate response to hypoxia. It
has been a long-standing concern that neutralization of VEGF
could counteract survival signaling in retinal neurons. Interest-
ingly, injection of low doses of VEGF accelerated restoration of
the physiological capillary bed and prevented preretinal neovas-
cularization in a mouse model of proliferative retinopathy (Dorrell
et al., 2010).
The highest expression level of VEGF in the kidney is in renal
podocytes, and some of the most comprehensive work
describing a role for VEGF as a survival factor in any organ
susceptible to diabetes complications has been done in renal
podocytes. Conditional deletion of VEGF in podocytes resulted
in a complete lack of endothelial and mesangial cells in mature
glomeruli and death within the first day of life (Eremina et al.,
2003). This finding strongly supports a role for VEGF in mainte-
nance of glomerular endothelial cells. Heterozygous knockout
of VEGF in podocytes of mice resulted in proteinuria and end-
stage renal failure in young adults (Eremina et al., 2003) and
was preceded by disappearance of endothelial cell fenestra-
tions, endothelial cell necrosis, effacement of podocyte foot
processes, and a dramatic loss of mesangial cells (Eremina
et al., 2003).
When diabetes was induced with streptozotocin in mice with
podocyte-specific knockout of VEGF, glomerular cell apoptosis,glomerulosclerosis, and proteinuria were all exacerbated
compared with nondiabetic controls (Sivaskandarajah et al.,
2012). As mentioned in an earlier section, established nephrop-
athy in mouse models can be improved by treatment with anti-
VEGF compounds. Future research should be able to reveal
whether promoting VEGF action on glomerular cells before onset
of nephropathy can prevent renal disease.
APC
Protein C has been known as an anticoagulant factor but more
recently was identified as a survival factor for renal glomerular
cells (Isermann et al., 2007). Thrombomodulin, a procoagulant
factor which activates protein C, was found to be highly ex-
pressed in glomeruli of mice but was downregulated in diabetes
(Isermann et al., 2007). Diabetic mice with a loss-of-function
thrombomodulin gene mutation had more albuminuria and
more severe glomerular pathology than diabetic wild-type
mice, whereas diabetic mice with a gain-of-function mutation
of the protein C gene had less albuminuria and glomerular
pathology (Isermann et al., 2007). The anticoagulant effects of
APC did not account for its protective actions. Rather, APC
was shown to counteract apoptosis of endothelial cells and
podocytes through activation of two of its receptors (Isermann
et al., 2007). Therefore, endothelial-derived APC appears to be
a protective factor with local survival effects for both podocytes
and endothelial cells in the glomerulus.
Efferocytosis and Autophagy
Apoptosis of plaque macrophages and foam cells is a prominent
feature of advanced atherosclerotic plaques. Susceptibility
to apoptosis is increased in insulin-resistant macrophages
because of impaired signaling through Akt or other antiapoptotic
pathways or due to activation of ER stress (Han et al., 2006;
Liang et al., 2004). Phagocytic clearance, or efferocytosis,
prevents postapoptotic necrosis. Efferocytosis is defective in
advanced plaques, and this contributes to formation of a necrotic
core. Impaired efferocytosis can thereby amplify the proinflam-
matory condition and lead to disruption of the fibrous cap of
the atherosclerotic plaque through release of matrix metallopro-
teases. Such events promote thrombosis through expression of
tissue factor and release of plasma membrane microparticles
from necrotic cells (Tabas, 2010).
Macrophage function in atherosclerotic plaques is also
affected by autophagy, the recycling of organelles and other
cytoplasmic components through lysosomal degradation
(Yamada and Singh, 2012). A specialized form of autophagy,
termed lipophagy, is also involved in the mobilization and degra-
dation of intracellular lipid and is impaired in obesity. Activation
of autophagy in plaque macrophages can prevent formation of
foam cells and limit atherosclerosis. This is seen in mice with
Wip1 knockout (Le Guezennec et al., 2012). Wip1 is a phospha-
tase which negatively regulates the ataxia telangiectasia
mutated (ATM) kinase. Wip1 knockout activates ATM in macro-
phages and initiates autophagy, which in turn increases choles-
terol efflux and prevents formation of macrophage foam cells (Le
Guezennec et al., 2012). Macrophage autophagy also prevents
apoptosis and promotes efferocytosis of apoptotic macro-
phages (Liao et al., 2012). Although not yet investigated, auto-
phagy of plaque macrophages is likely impaired in obesity and
type 2 diabetes, like lipophagy in other locations such as liver
(Yamada and Singh, 2012). Autophagy may also be an importantCell Metabolism 17, January 8, 2013 ª2013 Elsevier Inc. 29
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nephropathy (Kume et al., 2012).
Vascular Progenitor Cells
Bone-marrow-derived cells, including endothelial progenitor
cells (EPCs) and myeloid progenitors, contribute to postnatal
angiogenesis (Bautch, 2011). The mechanism for this is currently
not well characterized, despite intensive interest. It appears that
structural contribution by incorporation of EPC into newly
formed blood vessels plays a minor role. Release of proangio-
genic factors from EPC temporarily associating with neovascular
structures may be more important. In patients with diabetes,
both the number and function of EPC are impaired (Loomans
et al., 2004; Tepper et al., 2002). Differentiation of EPC from
bone-marrow-derived cells may also play a role (Tamarat et al.,
2004). eNOS is necessary for mobilization of EPC from the
bone marrow, as this phenomenon is impaired in eNOS
knockout mice (Aicher et al., 2003). Uncoupling of eNOS, with
synthesis of superoxide rather than NO by eNOS, could be one
mechanism for impaired EPC function. In fact, EPC function is
improved after inhibition of eNOS ex vivo in EPC isolated from
patients with diabetes (Thum et al., 2007). Interestingly, bone
marrow neuropathy may cause reduced mobilization of EPC.
Thus, rats with streptozotocin-induced diabetes had a reduction
in nerve terminals in bone marrow and denervation which re-
sulted in an increased number of EPC in the bone marrow, but
decreased release of EPC to the circulation. These abnormalities
were associated with an increase in retinal acellular capillaries
(Busik et al., 2009).
Transplantation of nondiabetic EPC to diabetic animals has
been shown to improve angiogenesis in peripheral ischemia.
Similarly, injection of a subpopulation of myeloid progenitor cells
differentiated into retinal macrophages known as microglia,
improved intraretinal angiogenesis and partly prevented patho-
logical, preretinal angiogenesis in ischemic retinopathy (Ritter
et al., 2006). Studies like these suggest that it may be possible
to promote repair of ischemic tissue in diabetes by therapy
aimed at improving mobilization, differentiation, and function of
EPCs or other progenitors.Conclusion
The most effective prevention of diabetic complications would
likely be to achieve perfect metabolic control and normalize
insulin resistance, but this goal is unrealistic in the foreseeable
future. A wealth of mechanistic information has accumulated
regarding the adverse effects of hyperglycemia and insulin
resistance on the vascular wall of arteries and the microvascu-
lature. Recognition of the importance of endogenous protective
factors in determining the course of diabetic vascular com-
plications is providing a new perspective for understanding
the development of diabetic complications. Characterizing
pathways controlled by protective factors should also provide
new opportunities for development of therapeutics effec-
tive at preventing or delaying the vascular complications of
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